Black Rock Inc. Travere Therapeutics, Inc. Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 7,644,789 shares of TVTX stock, worth $129 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,644,789
Previous 7,796,766
1.95%
Holding current value
$129 Million
Previous $60.1 Million
4.54%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding TVTX
# of Institutions
238Shares Held
101MCall Options Held
1.79MPut Options Held
555K-
Armistice Capital, LLC New York, NY8.87MShares$150 Million2.42% of portfolio
-
Janus Henderson Group PLC London, X07.53MShares$127 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.01MShares$84.8 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C34.8MShares$81.1 Million0.11% of portfolio
-
State Street Corp Boston, MA3.65MShares$61.7 Million0.0% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.09B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...